Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 2016. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, in accordance with DTR 3.1.4 R(1)(c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding specific personnel transactions rather than a financial performance report.
Material Changes
The filing discloses an increase in the notional allocation of GSK American Depositary Shares (ADSs) for a connected person. This change resulted from the revaluation of the cash element of a notional investment held within the GSK 401(K) plan as of March 31, 2016.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is strictly a notification of a specific transaction.
Important Facts for Investors
- Transaction Date: The company was advised of the transaction on April 1, 2016, relating to activity on March 31, 2016.
- Connected Person: Dr. K. Slaoui (Connected Person of Dr. M. M. Slaoui).
- Transaction Details: An increase of 9 ADSs.
- Valuation: The transaction occurred at a price of $40.55 per ADS.
- Reason: Revaluation of the cash element within the GSK 401(K) plan.